Aug 7, 2026

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:

• Introduction (0:00)
• Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17)
• Management of...

Aug 4, 2026

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:

• Introduction: Relative Impact of Targeted Treatment (0:00)
• HER2 Alterations (8:04)
• KRAS Mutations (24:25)
• MET Overexpression (30:34)
• ALK Fusions (32:34)
• ROS1 Fusions (42:36)
• RET Fusions (52:00)

CME information and...

Aug 3, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting ALK, ROS1 and RET — Maurice Pérol, MD 

CME information and select...

Aug 3, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1:  Therapeutic Approaches Targeting HER2, MET and KRAS G12C — John V Heymach, MD, PhD

CME information and select...

Jul 30, 2026

Featuring perspectives from Dr Joshua K Sabari, including the following topics:

• Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28....